| Dr Robert Choyce Humble, MD | |
|
500 W Broadway St, Missoula, MT 59802-4008 | |
| (406) 721-5600 | |
| (406) 329-7103 |
| Full Name | Dr Robert Choyce Humble |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 23 Years |
| Location | 500 W Broadway St, Missoula, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396034328 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 41659 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Patrick Hospital | Missoula, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Montana Clinic Pc | 2466365002 | 40 |
News Archive
A preliminary report suggests that genetic testing may help identify a marker in lymph nodes that is associated with an increased risk of colorectal cancer recurrence among patients in whom conventional testing indicates that those lymph nodes show no evidence of cancer spread, according to a study in the February 18 issue of JAMA.
Though the focus on typhoid fever traditionally has focused on Asia, where the disease is endemic, "[s]ince early November 2011, there has been a surge of typhoid fever outbreaks in central and southern Africa, affecting children and adults alike," Christopher Nelson, director of the Coalition against Typhoid (CaT) at the Sabin Vaccine Institute, and Ciro de Quadros, executive vice president of the Sabin Vaccine Institute, write in this Atlantic opinion piece.
Second Sight Medical Products Inc. announces today that the Argus II Retinal Prosthesis System, the world's first approved device intended to restore some functional vision for people suffering from blindness due to outer retinal degenerations, has become the first recipient of the French Government national healthcare reimbursement program entitled ‘Forfait Innovation'.
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.
› Verified 7 days ago
| Entity Name | Western Montana Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942253182 PECOS PAC ID: 2466365002 Enrollment ID: O20031110000361 |
News Archive
A preliminary report suggests that genetic testing may help identify a marker in lymph nodes that is associated with an increased risk of colorectal cancer recurrence among patients in whom conventional testing indicates that those lymph nodes show no evidence of cancer spread, according to a study in the February 18 issue of JAMA.
Though the focus on typhoid fever traditionally has focused on Asia, where the disease is endemic, "[s]ince early November 2011, there has been a surge of typhoid fever outbreaks in central and southern Africa, affecting children and adults alike," Christopher Nelson, director of the Coalition against Typhoid (CaT) at the Sabin Vaccine Institute, and Ciro de Quadros, executive vice president of the Sabin Vaccine Institute, write in this Atlantic opinion piece.
Second Sight Medical Products Inc. announces today that the Argus II Retinal Prosthesis System, the world's first approved device intended to restore some functional vision for people suffering from blindness due to outer retinal degenerations, has become the first recipient of the French Government national healthcare reimbursement program entitled ‘Forfait Innovation'.
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Choyce Humble, MD Po Box 7609, Missoula, MT 59807-7609 Ph: (406) 721-5600 | Dr Robert Choyce Humble, MD 500 W Broadway St, Missoula, MT 59802-4008 Ph: (406) 721-5600 |
News Archive
A preliminary report suggests that genetic testing may help identify a marker in lymph nodes that is associated with an increased risk of colorectal cancer recurrence among patients in whom conventional testing indicates that those lymph nodes show no evidence of cancer spread, according to a study in the February 18 issue of JAMA.
Though the focus on typhoid fever traditionally has focused on Asia, where the disease is endemic, "[s]ince early November 2011, there has been a surge of typhoid fever outbreaks in central and southern Africa, affecting children and adults alike," Christopher Nelson, director of the Coalition against Typhoid (CaT) at the Sabin Vaccine Institute, and Ciro de Quadros, executive vice president of the Sabin Vaccine Institute, write in this Atlantic opinion piece.
Second Sight Medical Products Inc. announces today that the Argus II Retinal Prosthesis System, the world's first approved device intended to restore some functional vision for people suffering from blindness due to outer retinal degenerations, has become the first recipient of the French Government national healthcare reimbursement program entitled ‘Forfait Innovation'.
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.
› Verified 7 days ago
Amethyst Smith, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-721-5600 Fax: 406-329-7103 | |
Dr. Kristin Ann Rauch, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2825 Fort Missoula Rd, #115, Missoula, MT 59804 Phone: 406-728-4292 Fax: 406-728-5770 | |
Dr. Dionne Drakulich, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2835 Fort Missoula Rd Ste 101, Missoula, MT 59804 Phone: 406-327-4640 Fax: 504-988-1846 | |
Jennifer Larson, ARNP Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3624 Brooks St Ste 101, Missoula, MT 59801 Phone: 888-227-3312 | |
Dr. Valerie A Knudsen, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2831 Fort Missoula Rd, Suite 306, Missoula, MT 59804 Phone: 406-327-4395 Fax: 406-327-4394 | |
Jesse J Pitt, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2825 Fort Missoula Road, Suite 225, Missoula, MT 59804 Phone: 406-721-1640 Fax: 406-721-2138 | |
Dr. Gregory O Utter, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Community Medical Center Physician Building 3, 2835 Fort Missoula Rd. Suite 304, Missoula, MT 59804 Phone: 406-327-3924 Fax: 406-327-3923 |